The world’s first allogeneic T-cell therapy — a type of universal immunotherapy treatment that relies on donor blood — was approved in Europe earlier this month. Not only this a game changer for the medical industry, it demands innovation from the logistics industry as well.
With this scientific leap, the possibility of having a single large batch of engineered cells to potentially treat hundreds of patients is becoming a reality.
Cold chain logistics is a relatively niche industry, and the...